Jazz Pharmaceuticals (JAZZ) Total Debt Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Jazz Pharmaceuticals | 14.64 Bn | 12.79 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.57% |
| Dec 31, 2025 | 20.66% |
| Sep 30, 2025 | 20.76% |
| Jun 30, 2025 | 20.59% |
| Mar 31, 2025 | 27.22% |
| Dec 31, 2024 | 30.61% |
| Sep 30, 2024 | 30.67% |
| Jun 30, 2024 | 28.94% |
| Mar 31, 2024 | 29.00% |
| Dec 31, 2023 | 29.05% |
| Sep 30, 2023 | 29.10% |
| Jun 30, 2023 | 29.14% |
| Mar 31, 2023 | 29.31% |
| Dec 31, 2022 | 29.35% |
| Sep 30, 2022 | 29.38% |
| Jun 30, 2022 | 29.21% |
| Mar 31, 2022 | 26.28% |
| Dec 31, 2021 | 24.41% |
| Sep 30, 2021 | 23.52% |
| Jun 30, 2021 | 41.71% |
| Mar 31, 2021 | 12.16% |
| Dec 31, 2020 | 12.00% |
| Sep 30, 2020 | 10.11% |
| Jun 30, 2020 | 9.01% |
| Mar 31, 2020 | 3.68% |
| Dec 31, 2019 | 3.67% |
| Sep 30, 2019 | 3.65% |
| Jun 30, 2019 | 6.00% |
| Mar 31, 2019 | 5.93% |
| Dec 31, 2018 | 23.75% |
| Sep 30, 2018 | 23.66% |
| Jun 30, 2018 | 23.58% |
| Mar 31, 2018 | 28.52% |
| Dec 31, 2017 | 28.19% |
| Sep 30, 2017 | 27.86% |
| Jun 30, 2017 | 29.00% |
| Jun 30, 2016 | 211.82% |
| Dec 31, 2015 | 89.96% |